drugset

drugset / Trial / NCT06490328

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

NCT06490328 ↗

Phase 3 Recruiting 154 enrolled Dongkook Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A phase 3, multi-center, single-group, open-label study to evaluate the efficacy and safety of DKF-MA102 in patients with prostate cancer.

Timeline

Start: 2024-05-30
Primary completion: 2025-05-20
Completion: 2025-05-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leuprolide	Other / unclassified	—	—

Indications